Form 4: RAPT Therapeutics Director Receives Annual RSU Grant

RAPT Therapeutics director Linda Kozick was granted 4,956 restricted stock units as part of the company's non-employee director compensation policy.

Summary

• Director Linda Kozick of RAPT Therapeutics, Inc. received an annual grant of 4,956 restricted stock units (RSUs).
• The grant date for these RSUs was January 30, 2026.
• Each RSU represents a contingent right to receive one share of common stock upon vesting.
• The RSUs are scheduled to fully vest on the first anniversary of the grant date, which is January 30, 2027.
• This grant was made under the Issuer's Amended & Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. It reflects standard corporate governance practices for director compensation and aligns director interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grant of restricted stock units to Director Linda Kozick aligns her interests with those of shareholders, as her compensation is tied to the company's future stock performance.
• The transaction is part of a pre-existing, disclosed compensation policy, indicating a structured approach to director remuneration.

Risks

• The value of the granted RSUs is subject to the future performance of RAPT Therapeutics' common stock, meaning the actual value realized by the director could be lower than the stock price at the time of grant if the stock declines.
• The RSUs are subject to a vesting period, meaning the director must remain with the company for the specified period to receive the shares.

Future Outlook

The filing indicates a future vesting event on January 30, 2027, for the granted restricted stock units, aligning director incentives with long-term company performance.

Industry Context

StockSavvy.ai notes that granting restricted stock units (RSUs) to non-employee directors is a common practice across the biotechnology and pharmaceutical industries. This method of compensation is widely adopted to attract and retain qualified board members while aligning their financial interests with long-term shareholder value creation, similar to practices seen at peers like Moderna or BioNTech.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is a standard practice in the biotechnology sector, comparable to compensation structures at companies such as Gilead Sciences, Amgen, and Biogen, which also utilize equity awards to incentivize board members.
• The vesting schedule, typically one year for annual grants, is consistent with common industry benchmarks for non-employee director equity compensation, ensuring continued engagement and alignment.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Director Linda Kozick constitutes a related party transaction, as she is a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value, as the value of the RSUs depends on the company's stock performance. It is a standard component of director compensation.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The granted restricted stock units are scheduled to fully vest on January 30, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine annual grant of restricted stock units to a non-employee director, consistent with established compensation policies. Such a transaction is generally expected and does not typically provide new information that would warrant a change in investment recommendation. It reinforces standard corporate governance and director alignment but lacks material operational or financial news to drive a 'buy' or 'sell' decision.

Keywords

RAPT Therapeutics, RAPT, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Linda Kozick, Equity Compensation